Impact of Intraovarian Injection of Platelet-Rich Plasma and Growth Factors on IVF Outcomes in Patients with Low Ovarian Reserve: A Randomized Controlled Trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517726-26-00

Enrollment

160

Registered

2025-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility

Brief summary

number of oocytes retrieved after intraovarian administration of the study treatment, PRGF Endoret® vs. placebo

Interventions

DRUGPLATELET CONCENTRATE

DRUGSuero Fisiológico Braun 0

DRUG9% disolvente para uso parenteral Cloruro de sodio

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
number of oocytes retrieved after intraovarian administration of the study treatment, PRGF Endoret® vs. placebo	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026